Human Papillomavirus Type 18 cis-Elements Crucial for Segregation and Latency.
Stable maintenance replication is characteristic of the latency phase of HPV infection, during which the viral genomes are actively maintained as extrachromosomal genetic elements in infected proliferating basal keratinocytes. Active replication in the S-phase and segregation of the genome into daughter cells in mitosis are required for stable maintenance replication. Most of our knowledge about papillomavirus genome segregation has come from studies of bovine papillomavirus type 1 (BPV-1), which have demonstrated that the E2 protein cooperates with cellular trans-factors and that E2 binding sites act as cis-regulatory elements in the viral genome that are essential for the segregation process. However, the genomic organization of the regulatory region in HPVs, and the properties of the viral proteins are different from those of their BPV-1 counterparts. We have designed a segregation assay for HPV-18 and used it to demonstrate that the E2 protein performs segregation in combination with at least two E2 binding sites. The cooperative binding of the E2 protein to two E2 binding sites is a major determinant of HPV-18 genome segregation, as demonstrated by the change in spacing between adjacent binding sites #1 and #2 in the HPV-18 Upstream Regulatory Region (URR). Duplication or triplication of the natural 4 bp 5'-CGGG-3' spacer between the E2 binding sites increased the cooperative binding of the E2 molecules as well as E2-dependent segregation. Removal of any spacing between these sites eliminated cooperative binding of the E2 protein and disabled segregation of the URR and HPV-18 genome. Transfer of these configurations of the E2 binding sites into viral genomes confirmed the role of the E2 protein and binding sites #1 and #2 in the segregation process. Additional analysis demonstrated that these sites also play an important role in the transcriptional regulation of viral gene expression from different HPV-18 promoters.
University of Tartu, Institute of Technology, Tartu, Estonia.
Mart
M
Ustav
University of Tartu, Institute of Technology, Tartu, Estonia.
Fernando Rodriguez
FR
Castaneda
University of Tartu, Institute of Technology, Tartu, Estonia.
Tormi
T
Reinson
Icosagen Cell Factory OÜ, Tartu, Estonia.
Andres
A
Männik
University of Tartu, Institute of Technology, Tartu, Estonia; Icosagen Cell Factory OÜ, Tartu, Estonia; Estonian Academy of Sciences, Tallinn, Estonia.
Mart
M
Ustav
D001665:Binding Sites / Q000235:genetics; D045744:Cell Line, Tumor; D020090:Chromosome Segregation / Q000235:genetics*; D004261:DNA Replication; D004279:DNA, Viral / Q000235:genetics; D004268:DNA-Binding Proteins / Q000378:metabolism; D024202:Electrophoretic Mobility Shift Assay; D015967:Gene Expression Regulation, Viral; D052161:Human papillomavirus 18 / Q000235:genetics* / Q000502:physiology; D006801:Humans; D019169:Jurkat Cells; D015603:Keratinocytes / Q000821:virology; D009856:Oncogene Proteins, Viral / Q000235:genetics*; D010957:Plasmids / Q000235:genetics; D011401:Promoter Regions, Genetic / Q000235:genetics; D011485:Protein Binding / Q000235:genetics; D050436:Regulatory Elements, Transcriptional / Q000235:genetics*; D017735:Virus Latency / Q000235:genetics*; D014779:Virus Replication / Q000235:genetics
D004279:DNA, Viral; D004268:DNA-Binding Proteins; D009856:Oncogene Proteins, Viral; C069102:oncogene protein E2, Human papillomavirus type 18